PDCD1 and neuropathy: When comparing pembrolizumab and nivolumab, there was no statistically significant difference in the documented neuropathy associated with PD-1 inhibitor exposure (Table 1; OR 1.058, 95% CI 0.913–1.226, p = 0.4554), after adjusting for other covariates.